The efficacy and safety of <i>Saccharomyces boulardii</i> in addition to antofloxacin-based bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication: a single-center, prospective randomized-control study.

Authors:
He XJ; Wang XL; Sun DJ; Huang XY; Liu G and 5 more

Journal:
Therap Adv Gastroenterol

Publication Year: 2023

DOI:
10.1177/17562848221147763

PMCID:
PMC9893347

PMID:
36742013

Journal Information

Full Title: Therap Adv Gastroenterol

Abbreviation: Therap Adv Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare that there is no conflict of interest."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the National Natural Science Foundation of China [Grant No. 82100687], Science and Technology Project of Fujian Province [Grant No. 2018Y9116, 2020J05283], Sailing Project of Fujian Medical University [Grant No. 2019QH1283, 2019QH1286], School Management Project of Fujian University of Traditional Chinese Medicine [Grant No. XB2022143], Outstanding Youth Training Program of 900TH Hospital [Grant No. 2019Q03]."

Evidence found in paper:

"Trial registration number: ChiCTR2200056931."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025